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Background: The treatment of iron deficiency anemia in children with inflammatory bowel disease is a particular
challenge and often insufficient. Absorption of orally given iron may be impaired by intestinal inflammation and
treatment with oral iron may aggravate intestinal inflammation. This retrospective study is the first to describe the
use of intravenous ferric carboxymaltose (FCM) in the pediatric setting.
Methods: All subjects who had received at least one dose of FCM intravenously in the observation period were
included in this analysis with data collected for up to 3 months post last FCM dose.
Results: In total, 72 children between 0 and 18 years with underlying gastrointestinal disorders had been treated
for concomitant iron deficiency anemia. The majority of patients had Crohn’s disease (40.3%) or ulcerative colitis
(30.5%). The total number of FCM administrations was 147, the mean number per patient was 2.0 and the mean
cumulative dose 821 mg iron (median single dose: 500 mg; max. 1000 mg). Post administration of FCM, correction
of iron deficiency anemia was observed with improved mean hemoglobin levels from 9.5 g/dL at baseline to
11.9 g/dL within 5–12 weeks. Decreases in white cell count, platelets and C-reactive protein were observed post
FCM, potentially suggesting reduced inflammation with iron repletion. Three subjects reported mild adverse drug
reactions related to FCM; two of these were considered to be potentially related to long duration of administration
and to high volume of saline solution for dilution. As such, the method of administration was amended to have a
maximum infusion time of 60 minutes and dilution with less than or equal to 100 mL saline solution.
Conclusions: Overall FCM was well tolerated in this pediatric population and appeared to be effective in correcting
iron deficiency anemia. We cannot exclude that the correction of iron deficiency anaemia is in some part due to
the treatment of the underlying disease and not related to the iron supplementation only.
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Children with inflammatory bowel disease (IBD) are at
increased risk for iron deficiency for multiple reasons:
increased requirements during growth, insufficient diet-
ary intake, decreased absorption of dietary iron and in-
testinal blood loss. In a recent study 75% of children
with IBD were anaemic at diagnosis, and 90% of children* Correspondence: martin.laass@uniklinikum-dresden.de
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unless otherwise stated.with Crohn’s disease and 95% of children with ulcerative
colitis had iron deficiency at diagnosis. Even at two years
follow-up, 30% of children with IBD were anaemic and
70% of children with Crohn’s disease and 65% with ulcera-
tive colitis were still iron deficient [1]. As such, anemia is
more common in children than in older IBD patients [2].
In IBD usually two forms of anemia coexist: iron-
deficiency anemia (IDA) and anemia of chronic disease.
Therefore, careful evaluation of iron status, including la-
boratory parameters like hemoglobin (Hb), mean cor-
puscular volume, serum ferritin, transferrin saturation, istd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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course of disease. For the correct assessment of iron sta-
tus, parameters of inflammation such as C-reactive protein
must also be taken into consideration. Similar to adult set-
tings, caution is recommended with interpretation of iron
stores based on serum ferritin, as this acute phase reactant
may be normal or elevated even in the presence of iron
deficiency. For this reason, ferritin levels up to 100 μg/L
may still be consistent with iron deficiency, if there are in-
dications for inflammation [3,4].
IDA may negatively impact quality of life due to in-
creased chronic fatigue and reduced energy metabolism,
these being due to the role of iron in myoglobin as well as
numerous other metabolic and even cognitive functions
[5]. Hence, IDA warrants early and appropriate interven-
tion to relieve not only acute symptoms of iron deficiency
but also the longer-term potential consequences. The
treatment of IDA is a particular challenge in the IBD
population; on the one hand iron absorption may be im-
paired by intestinal inflammation, whilst on the other
hand oral iron treatment may worsen IBD symptoms by
aggravating intestinal inflammation [6].
There is a high intolerance and non-adherence to oral
iron in children and adults due to the side effects like nau-
sea, abdominal pain and constipation [7]. With intravenous
preparations intestinal absorption can be bypassed and iron
replacement can be achieved with one or two doses of the
newer high-dose preparations. Although the rationale is
compelling, unfortunately in the pediatric setting very few
studies have examined the role of intravenous iron for cor-
rection of IDA. In contrast, the role of intravenous iron is
well established as a therapeutic option in numerous areas,
including IBD, in the adult population [8].
There are a number of different intravenous iron for-
mulations: high and low molecular weight iron dextran,
iron sucrose, ferric gluconate, ferric carboxymaltose and
ferumoxytol. As intravenous iron therapies have differ-
ent physico-chemical properties, the administration may
require more frequent lower individual doses (e.g. intra-
venous iron sucrose or gluconate) whereas more stable
preparations (e.g. iron dextran or ferric carboxymaltose)
can be given as large single intravenous doses. Concerns
regarding the safety of intravenous iron preparations refer
particularly to high molecular weight dextran formula-
tions, which have an increased risk of anaphylaxis result-
ing from anti-dextran antibodies [9]. Newer intravenous
iron drugs such as iron sucrose and ferric carboxymaltose
(FCM) appear to have better safety profiles [10,11].
FCM has been studied in numerous therapeutic areas
including IBD [11-13] and has almost 1.2 million patient
years of exposure as of June 2013 (based on an average
dosing of 1,350 mg iron per patient) [14]. The product
was first approved in Europe in 2007 for the correction
of iron deficiency in patients over the age of 14 years.FCM is dextran-free and may be administered in large
single doses up to 1000 mg iron either as an infusion
(limited at 20 mg iron per kg body weight) or injection
(limited at 15 mg iron per kg body weight) and does not
require a test dose.
To date, no data have been published on the use of
FCM in the pediatric population and hence this retro-
spective analysis is the first study to provide initial expe-
riences in treatment of IDA in children with IBD and
other gastrointestinal diseases associated with IDA.
Methods
All patients 18 years and younger treated with FCM for
IDA during the period 1 September 2008 and 30 April
2013 at the University Hospital for Children and Adoles-
cents, Dresden, Germany were considered for inclusion.
Anemia was defined as Hb below the lower reference
value (according to age and gender) of the local labora-
tory (Additional file 1: Table S1). Anemia was classified
as IDA when the following values were below the lower
reference value of the laboratory: mean corpuscular vol-
ume of the erythrocytes, transferrin saturation and fer-
ritin (<20 μg/L). Anemia was also classified as IDA when
the soluble transferrin receptor or the soluble transfer-
rin receptor/log ferritin ratio was elevated (Additional
file 1: Table S1). When parameters of inflammation
were present (e.g. clearly elevated C-reactive protein,
erythrocyte sedimentation rate), ferritin values up to
100 μg/L were regarded consistent with IDA.
Patients receiving at least one dose of FCM (Ferinject®;
Vifor Pharma, St Gallen, Switzerland) had data tran-
scribed to a case report form and were included in this
retrospective analysis. To avoid selection bias, all pa-
tients treated with FCM during the period, irrespective
of diagnosis or outcome, were documented.
The study was approved by the local ethics committee
of the Technische Universität Dresden (EK 411122010).
Ethical permission for collection of anonymous data was
granted prior to transcription from patient medical re-
cords to a case report form. No interventional procedures
or changes to current practice of patient management
were required and all treatment decisions had been made
prior to the initiation of this observational study. In
addition, parents of children younger than 14 years at time
of receiving FCM gave informed consent for the off-label
use of FCM (as the product was approved only for use in
patients 14 years or older at the time of administration).
Collected data included demography, significant medical
history and disease status. Additionally, information on
FCM use including date and dose administered as well as
route was recorded. Iron requirements had been deter-
mined using the Ganzoni formula at the time of treatment
[15,16]. Standard laboratory parameters from routine med-
ical practice along with concomitant medications taken






Mean (SD) 11.8 (4.86)
Min, max 0, 18
Median 13.5
Interquartile range 8, 15.5
Previous oral iron use, n (%) 39 (54.2)
Medical history, n (%)
Crohn’s disease 29 (40.3)
Ulcerative colitis 22 (30.5)
Celiac disease 4 (5.6)
Gastroesophageal reflux disease 2 (2.8)
Helicobacter pylori gastritis 2 (2.8)
Oesophageal varices bleeding 2 (2.8)
Chronic diarrhoea 1 (1.4)
Hyper-IgM syndrome 1 (1.4)
Intestinal vascular malformation 1 (1.4)
Ulcus ventriculi 1 (1.4)
Others 7 (9.7)
Concomitant medication, n (%)





Ferrous glycine sulphate 15 (20.8)
Metronidazole 10 (13.9)
Infliximab 9 (12.5)
Escherichia coli Nissle 1917 9 (12.5)
Cyclosporine 5 (6.9)
Most often used concomitant medication taken at any time during the
observation period (i.e. 3 months prior and 3 months post administration of
FCM). SD: Standard deviation.
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were recorded as well as adverse events documented up to
three months post drug administration.
Laboratory parameters included Hb, mean corpuscular
volume, hematocrit, mean corpuscular Hb, mean corpus-
cular Hb concentration, serum ferritin level, transferrin
saturation, soluble transferrin receptor, soluble transferrin
receptor/ log ferritin ratio, reticulocytes, reticulocyte Hb,
red blood cell distribution width, white blood cell count,
absolute neutrophil count, platelets, C-reactive protein, as-
partate transaminase, alanine transaminase, gamma gluta-
myl transferase and phosphate. Due to the retrospective
nature of the study and limited sample size, laboratory pa-
rameters were grouped in time periods. This included pre-
FCM (any value available from 12 weeks prior to first
dose), day of first FCM administration (which is generally
referred to as baseline unless missing, in which cases
values from pre-FCM were used as baseline) and then in
ranges of weeks, specifically weeks 0–2, 2–4, 5–8 and 9–
12, in which each range included values from within the
specified period (Weeks 0–2 comprise days 1 to 14 and
weeks 2–4 comprise days 15 to 28).
The statistical analysis was descriptive only. Continu-
ous data were summarised by mean, standard deviation,
median, lower and upper quartiles, minimum and max-
imum values. Analysis of variance (ANOVA) or analysis
of covariance (ANCOVA) was used for comparison. Cat-
egorical data were summarised by the number and per-
centage of subjects in each category.
Results
In total, 72 children and adolescents with underlying
gastrointestinal disease and IDA were treated with FCM
during the period of 1 September 2008 and 30 April 2013.
Similar numbers of female and male subjects were treated
with a mean age of 12.7 years (range: 0 to 18 years). The
youngest patient was an eleven months old infant after
liver transplantation for biliary atresia. The majority had
Crohn’s disease (40.3%) or ulcerative colitis (30.5%) and
were receiving concomitant immunosuppressive therapy
for their underlying disease. In all cases, the reason for ini-
tiating FCM was IDA and just over half of the patients
had previous oral iron use. Demographics and additional
baseline details are further described in Table 1. 37/72
(51.3%) of our patients were younger than 14 years when
they received their first dose of FCM.
The total number of FCM administrations was 147 and
the mean number per patient was 2.0. The mean cumula-
tive dose of intravenous FCM was 821 mg iron given in
two single infusions (median dose: 500 mg iron diluted in
100 mL saline over 66 minutes, max. dose: 1000 mg). On
average, patients received iron dosing at 12 mg/kg body
weight with a maximum single administration of 32 mg
iron per kg body weight in a 9 year-old girl weighing31 kg. Whilst the majority of individual doses were admin-
istered at levels <15 mg/kg, 16 patients received at least 1
dose ≥15 mg/kg and 7 received a dose >20 mg/kg. Cal-
culated baseline iron requirements (using the Ganzoni
formula) ranged from 100 to 1700 mg iron and closely
matched the doses given to patients. Details are de-
scribed in Table 2. During administration of FCM and
until two hours thereafter, patient’s oxygen saturation,
heart rate and blood pressure were closely monitored.
Post administration of FCM, correction of IDA was
observed with early reticulocyte level increases from
Table 2 Summary of ferric carboxymaltose (FCM) use and
iron dosing
Total n 72
Total cumulative iron dose [mg]
Mean (SD) 820.8 (741.04)
Median 500.0
Min, max 50, 3150
Amount of iron per dose [mg]
Mean (SD) 406.7 (203.07)
Median 500.0
Min, max 50, 1000
Total number of administrations 147
Total number of administrations per patient
Mean (SD) 2.0 (1.75)
Median 1.0
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Hb concentration with values evolving from a baseline of
9.5 g/dL (5.9 mmol/L) to 11.4 g/dL (7.1 mmol/L) within
5–8 weeks and stabilizing at 11.9 g/dL (7.4 mmol/L) by
week 9–12 (Figure 1). Similar to Hb, the mean corpuscular
volume levels were low at baseline indicating microcytic
anemia and were seen to improve rapidly post FCM ad-
ministration and stabilize for the duration of the observa-
tional period (Figure 2). The measured iron parameters
demonstrated repletion of iron with a peak at approxi-
mately 2 weeks post administration that thereafter plat-
eaued with values in the normal or target range in most
patients (Figure 3).
In addition to the above changes in relation to Hb and
iron parameters, decreases in white cell count, platelets
and C-reactive protein were also observed post FCM ad-
ministration. Mean white cell count was observed to de-
crease from a value of 8.6 Gpt/L at baseline (prior to FCM
administration) to a value of 7.5 Gpt/L between weeks 5–
8, whilst platelet levels decreased from 487 Gpt/L to
values of 376 GPt/L by weeks 5–8 and remained at this
level thereafter. Decreases were also observed for mean C-
reactive protein levels with values declining from an initial
12.8 mg/L at baseline to values of 7.4 and 6.0 mg/L by
weeks 5–8 and weeks 9–12 respectively (Figure 4).
Most patients had values within normal range for as-
partate transaminase (AST), alanine transaminase (ALT),gamma glutamyl transferase (GGT) and phosphate with
no excursions that led to a need to discontinue FCM or
delay dosing.
The majority of subjects (69 of 72, 95.8%) received con-
comitant medications during the 3 months following last
dose of FCM. The most frequently reported concomitant
medications were mesalazine, omeprazole and prednisol-
one. These medications are consistent with treating the
underlying aetiology of the included population.
In relation to safety, 3 subjects reported adverse drug
reactions to FCM. The first event was seen in a 17-year-
old male who experienced mild urticaria on the first day
of treatment with FCM, which resolved without treat-
ment the following day. He received two further infu-
sions of FCM and no further adverse drug events were
recorded with subsequent doses. The second event oc-
curred in a 5-year-old male who experienced mild oedema
of the palms and fingers of both hands on the first day of
treatment with FCM. After antihistaminic treatment (with
oral dimetinden maleat) symptoms resolved the same day.
The subject received a total of three infusions of FCM and
no reaction was observed with the other administrations.
Both mild adverse drug reactions were considered poten-
tially related to long duration of administration and high
volume of saline for dilution, which was not in accordance
with the manufacturer’s instruction to avoid dilution to
iron concentrations below 2 mg/mL. After altering the
method of administration to a dilution with 100 mL saline
or less and an infusion time not exceeding 60 minutes,
only one further adverse drug reaction occurred. The third
event occurred in a 15-year old female who experienced
mild urticaria on the first and only day of treatment with
FCM. Concomitant medication (dimetindene maleate)
was administered and the event resolved on the same day.
The event was considered related to FCM by the investi-
gator and the subject only received one infusion of FCM.
No serious or severe adverse drug events were reported in
the treated patients.
Discussion
The rationale for adopting the use of ferric carboxymal-
tose in our pediatric patients was to avoid poorly toler-
ated oral iron therapy and permit higher single doses of
iron to be administered in shorter time periods with less
overall numbers of infusions. The large pool of pub-
lished clinical data, including studies performed in adult
IBD patients, helped support our decision for imple-
menting this product in our clinical practice. Until then
we had prescribed oral iron preparations, used intravenous
ferrous gluconate - often requiring multiple infusions - or
tolerated IDA in our pediatric IBD patients. After having
treated patients with FCM for nearly 5 years, we felt it












Pre-FCM FCM day 1 Week 0-2 Week 2-4 Week 5-8 Week 9-12
Reticulocytes Hemoglobin
Figure 1 Time course of reticulocytes and hemoglobin. Given are reticulocytes per 1000 erythrocytes (left axis, black line) and hemoglobin in
g/dL (right axis, red line). FCM day 1 refers to day of first FCM administration, but blood for assessment of laboratory parameters was drawn before
FCM administration. This is referred to as baseline (unless values from this day were missing, in which cases Pre-FCM values were used). Additional FCM
doses may have been administered after this to achieve iron repletion. Weeks 0–2 comprise days 1 to 14 and weeks 2–4 comprise days 15 to 28.
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a per patient basis, with a median of one infusion per pa-
tient to deliver 500 mg iron (mean dose was 821 mg iron
administered in two infusions). The effectiveness of dosing
to correct iron levels was assessed by serum ferritin (pro-






Pre-FCM FCM day 1 Week 0
Mean Corpuscu
Figure 2 Time course of mean corpuscular volume over observationa
FCM day 1 refers to day of first FCM administration, but blood for assessme
is referred to as baseline (unless values from this day were missing, in which c
administered after this to achieve iron repletion. Weeks 0–2 comprise days 1 t(providing insight on circulating iron available for use),
soluble transferrin receptor and red blood cell parameters.
Serum ferritin levels were returned to ‘normal’ targets by
the end of the observation period; however, the transferrin
saturation initially increased (at weeks 2–8) to near target
ranges, but were then seen to decrease again by week 12-2 Week 2-4 Week 5-8 Week 9-12
lar Volume (MCV)
l period. Given are mean values in femtoliter (fL) and standard errors.
nt of laboratory parameters was drawn before FCM administration. This
ases Pre-FCM values were used). Additional FCM doses may have been
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Pre-FCM FCM day 1 Week 0-2 Week 2-4 Week 5-8 Week 9-12
STrRec / Ferritin index
Figure 3 Time course of iron parameters. Given are mean value and standard errors for serum concentration of transferrin saturation (in %),
ferritin (in μg/L) and soluble transferrin receptor (in mg/L) and for soluble transferrin receptor/ log ferritin ratio during the course of the
observation period. FCM day 1 refers to day of first FCM administration, but blood for assessment of laboratory parameters was drawn before
FCM administration. This is referred to as baseline (unless values from this day were missing, in which cases Pre-FCM values were used). Additional FCM
doses may have been administered after this to achieve iron repletion. Weeks 0–2 comprise days 1 to 14 and weeks 2–4 comprise days 15 to 28.
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iron utilization in the bone marrow, underestimation of
total calculated iron deficit and/or ongoing losses which
suggest a need for additional iron to avoid recurrent IDA.
In terms of anemia treatment, a secondary efficacy par-
ameter, a rapid increase in the reticulocyte count was ob-
served within 2 weeks of iron administration using FCM
and translated into anemia correction already at approxi-
mately 4 weeks. Over the observational period, the Hb
levels were seen to evolve from a pre-treatment mean of
9.5 g/dL (5.9 mmol/L) to an acceptable 11.4 g/dL
(7.1 mmol/L) by 5–8 weeks and achieve acceptable con-
centrations of 11.9 g/dL (7.4 mmol/L) by weeks 9–12.
In recent studies of FCM use in an adult IBD population,
similar results were observed, namely the correction of Hb
to acceptable levels, albeit with a large proportion of pa-
tients not achieving or maintaining appropriate iron reple-
tion. In this study the authors concluded that sufficient
doses of iron may not have been given and that perhaps the
current guidelines are not entirely suitable for optimal
anemia management [13]. In the follow-up study to as-
sess maintenance therapy (beyond initial iron deficiencycorrection) it was confirmed that anemia recurrence
could be avoided in a large percentage of patients by
means of continued iron management based on de-
creased serum ferritin values [17]. Whilst not currently
our routine practice nor part of this observational study,
such a maintenance strategy may warrant further inves-
tigation and provide rationale for more routine moni-
toring of iron parameters in our patients.
Although anemia and iron deficiency are highly preva-
lent in pediatric patients with IBD, focus of treatment
lies often only on intestinal inflammation, which results
in a slow hematological recovery [18]. Further to anemia
management, the administration of iron also appeared to
result in decreases respectively normalization of white cell
count, platelets and C-reactive protein. These observations
might suggest a role of iron therapy also in reducing in-
flammation and normalization of secondary thrombocyto-
sis in IBD, however should be interpreted with caution, as
medication changes were not captured as part of this
study. As the majority of our patients received concomi-
tant, mostly immunosuppressive, medication, such find-
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Figure 4 Time course of white blood cell count, platelets and C-reactive protein. White blood cell count and platelets are given in Gpt/L
and C-reactive protein (CRP) in mg/L. Given are mean values and standard errors.
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seen in other studies using FCM, where a decrease of
platelets was observed independent of inflammation
markers such as C-reactive protein [19]. Therefore, de-
creases in platelet count in our study may reflect nor-
malized bone marrow activity rather than reduced
inflammation.
As with all intravenous iron preparations, there was a
potential for side effects and hence tolerability was
closely monitored during administrations. When initially
using the medication, we adopted what we believed
would be a safer approach and diluted FCM beyond rec-
ommendations provided in the product label and admin-
istered the product very slowly via infusion. However,
this may have resulted in two events seen that were con-
sidered related to the study drug, namely a case of urti-
caria and one of mild oedema of the palms and fingers
of both hands. As described above, these events were
considered to be related to (a) long duration of drug ad-
ministration and (b) high volume of saline for dilution of
FCM. The exact mechanism is not known but may have
been secondary to excess dilution leading to less stable
complex (as the stability is dependent on the concentra-
tion equilibrium of the sodium hydroxide, iron [as iron(III)-hydroxide] and carboxymaltose). The method of ad-
ministration was consequently amended to have a max-
imum infusion time of 60 minutes and dilution with
100 mL saline or less.
The authors recognize the limitations of this retrospect-
ive observational study, for example that a comparator
arm is lacking which would permit any claims of efficacy
or safety in comparison to alternative options. Nonethe-
less, to minimize bias, all patients treated with FCM dur-
ing the period were documented, regardless of outcome.
The dosing and administration were per routine clinical
practice and not per any pre-specified protocol. Patients
received doses at the discretion of the treating physician
and as such, this study provides insights about product
tolerance and effectiveness in day-to-day clinical practice,
something not so easily observed in controlled studies.
Due to the observational nature of this study, we cannot
confirm if the correction of iron deficiency anaemia is re-
lated to the iron supplementation only or also in some
part to the treatment of the underlying active disease. This
is compounded due to the limitation within our data col-
lection which did not include disease activity at the time
of iron treatment and hence we are unable to distinguish
clearly between patients with active disease and those in
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ies may be required to confirm the true impact of the
iron therapy.
These initial experiences using FCM suggest that this
non-dextran based intravenous iron may be well toler-
ated and suitable for use in the correction of iron defi-
ciency anemia also in pediatric patients, especially for
those with IBD. The option to give higher dose single in-
jections or infusions may be of considerable benefit in
the management of care in this special population. Cur-
rently, the product is approved only for use in patients
14 years of age or older and hence, further clinical stud-
ies are warranted to confirm the above observations.
Conclusions
Overall FCM appeared to be safe and effective in correct-
ing iron deficiency anemia in this pediatric population.
Additional file
Additional file 1: Table S1. Reference ranges for blood tests - used in
the study - at various ages.
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